B. Riley Wealth Advisors Inc. Boosts Stake in United Therapeutics Co. (NASDAQ:UTHR)

B. Riley Wealth Advisors Inc. boosted its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 10.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,067 shares of the biotechnology company’s stock after acquiring an additional 99 shares during the period. B. Riley Wealth Advisors Inc.’s holdings in United Therapeutics were worth $340,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also made changes to their positions in the company. Renaissance Technologies LLC grew its stake in United Therapeutics by 1.1% during the 2nd quarter. Renaissance Technologies LLC now owns 2,174,692 shares of the biotechnology company’s stock valued at $692,748,000 after purchasing an additional 22,978 shares during the last quarter. LSV Asset Management increased its stake in shares of United Therapeutics by 82.5% during the second quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company’s stock worth $307,837,000 after purchasing an additional 436,851 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of United Therapeutics by 4.0% during the second quarter. Dimensional Fund Advisors LP now owns 585,969 shares of the biotechnology company’s stock valued at $186,656,000 after acquiring an additional 22,683 shares during the last quarter. Pacer Advisors Inc. raised its stake in United Therapeutics by 19.6% in the 2nd quarter. Pacer Advisors Inc. now owns 561,834 shares of the biotechnology company’s stock valued at $178,972,000 after purchasing an additional 92,240 shares during the last quarter. Finally, Swedbank AB purchased a new position in shares of United Therapeutics in the first quarter worth about $97,316,000. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

United Therapeutics Price Performance

UTHR stock opened at $349.85 on Tuesday. The firm has a market cap of $15.52 billion, a P/E ratio of 16.54, a price-to-earnings-growth ratio of 1.28 and a beta of 0.57. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.18 and a current ratio of 4.35. United Therapeutics Co. has a 1 year low of $208.62 and a 1 year high of $366.08. The stock has a 50-day simple moving average of $344.35 and a 200-day simple moving average of $301.02.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share for the quarter, missing the consensus estimate of $6.33 by ($0.48). United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. The business had revenue of $714.90 million for the quarter, compared to analyst estimates of $691.87 million. During the same quarter in the prior year, the business earned $5.24 earnings per share. The firm’s revenue was up 19.8% on a year-over-year basis. On average, equities analysts predict that United Therapeutics Co. will post 24.71 earnings per share for the current fiscal year.

Insider Buying and Selling

In other United Therapeutics news, CFO James Edgemond sold 7,792 shares of the company’s stock in a transaction that occurred on Monday, September 30th. The stock was sold at an average price of $358.62, for a total transaction of $2,794,367.04. Following the sale, the chief financial officer now owns 4,802 shares in the company, valued at $1,722,093.24. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. In other United Therapeutics news, CFO James Edgemond sold 7,792 shares of United Therapeutics stock in a transaction on Monday, September 30th. The shares were sold at an average price of $358.62, for a total value of $2,794,367.04. Following the completion of the transaction, the chief financial officer now owns 4,802 shares of the company’s stock, valued at $1,722,093.24. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Martine A. Rothblatt sold 269 shares of the stock in a transaction on Monday, August 26th. The stock was sold at an average price of $348.41, for a total transaction of $93,722.29. Following the sale, the chief executive officer now directly owns 130 shares in the company, valued at $45,293.30. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 104,644 shares of company stock worth $35,186,166. Corporate insiders own 12.50% of the company’s stock.

Analysts Set New Price Targets

Several research firms have issued reports on UTHR. StockNews.com cut United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, August 2nd. TD Cowen lifted their price objective on United Therapeutics from $270.00 to $350.00 and gave the company a “buy” rating in a research note on Thursday, July 11th. Morgan Stanley lowered United Therapeutics from an “overweight” rating to an “equal weight” rating and increased their target price for the company from $310.00 to $321.00 in a report on Thursday, July 11th. UBS Group raised their price objective on shares of United Therapeutics from $300.00 to $370.00 and gave the stock a “buy” rating in a report on Monday, July 8th. Finally, Bank of America cut their target price on United Therapeutics from $303.00 to $280.00 and set an “underperform” rating on the stock in a research report on Thursday, August 1st. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $357.17.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.